Baidu
map

Nat Commun:遏制95%的前列腺癌细胞生长!新型药物问世!

2018-10-25 Michael,Zoe 转化医学网

来自纽约大学的研究人员利用计算机辅助技术来研究新蛋白质—蛋白质间的相互作用,进而开发出一种全新的抗前列腺癌药物。该研究的最新研究发表于最新的《Nature Comunnications》杂志。

前列腺癌一直是临床上男性发病率最高的肿瘤之一。但由于其特殊的解剖位置以及其独特的信号调控机制,其临床治疗一直困扰着临床肿瘤医生以及各国的科研人员。究其原因,前列腺癌肿瘤细胞容易对当前的肿瘤治疗方案产生抗药性,进而大大降低患者的治疗效果。来自纽约大学的研究人员利用计算机辅助技术来研究新蛋白质—蛋白质间的相互作用,进而开发出一种全新的抗前列腺癌药物。该研究的最新研究发表于最新的《Nature Comunnications》杂志。

来自美国纽约大学的一项研究发现,一种新型分子可作用于驱动前列腺癌生长的基因进而阻断肿瘤的生长。该研究的主要负责任人Susan Logan博士表示,“他们的工作重点不是像先前的工作那样继续制造旧的药物,而是重新开发药物样分子的全新作用”。

来自医学院和纽约大学的联合研究小组发现,与未经处理的细胞相比,他们的“环状拟肽”使培养皿中前列腺癌细胞的生长减少了95%,同时,实验药物也阻断了活体动物试验中肿瘤生长关键的生长信号。纽约化学Kent Kirshenbaum 教授表示,“他们设计的拟肽专门用于攻击那些目前“不可能摧毁的目标”,例如导致前列腺癌的进展的关键靶点”。



该研究化合物通过干扰蛋白质β连环蛋白和T细胞因子(TCF)转录因子之间的相互作用来阻止肿瘤细胞生长,这些蛋白质可通过转化作用使细胞持续增殖。虽然这些基因对于前列腺组织的早期生长至关重要,但这种基因活动通常在成年时期被下调,因此只有重新激活这些基因才可能导致癌症的发生。



与许多现有药物不同,新化合物不会靶向先前明确的前列腺癌雄激素激素信号。大多数接受抗雄激素药物治疗的患者在数月便会出现癌症复发的情况,因此这就需要寻求其他治疗策略。先前大部分研究都集中在前列腺肿瘤中发生异常的Wnt蛋白信号,但没有一种靶向药物进入临床。

Wnt可以导致蛋白质β-连环蛋白在细胞核中积聚,同时在细胞核中诱导底物基因的表达。在这项新研究之前,研究团队花了数年时间设计了一类称为拟肽的物质,其大小足以与β连环蛋白及TCF相互作用的表面相结合。

新一代的计算机模拟工具使团队能够及早了解候选药物如何更好地靶向其蛋白底物。经过虚拟测试后,研究小组合成并在癌细胞在三维空间中验证了这些化合物。

在这些实验中,与未处理的癌细胞相比,环状拟肽在22天内减少了约95%的抗性前列腺癌细胞生长,相比之下,用未经修饰的拟肽形式处理细胞的生长减少仅为40%。同时,这些化合物还能降低雄激素激素信号,具备双重抗癌作用。



研究人员还希望证明他们合成的化合物可以阻止活体动物中的β连环蛋白信号。他们选择斑马鱼模型进行了相关实验,研究小组发现它们的环状拟肽可通过阻断过度活跃的β连环蛋白与TCF相互作用。这也从侧面证明了该化合物的抗癌作用。该团队将很快测试该药物对小鼠体内培养的人前列腺癌细胞的作用。

原始出处:Jeffrey A. Schneider, Timothy W. Craven, Amanda C. Kasper, et al. Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer. Nat Commun. 23 October 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2019-03-23 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2019-01-15 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-27 sam2000jie

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-26 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-26 phoebeyan520

    学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-25 121728bam55暂无昵称

    是人们的一种希望

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1883372, encodeId=79c218833e236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Mar 23 01:04:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087443, encodeId=1772208e44320, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jan 15 21:04:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350618, encodeId=ba193506185c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3Xj3dPpicVeGMtJVVf6ictxZkIbnfAicknI9T9Sic1GH3tiaC7Dl2R75mclpwGRcAaPicKInqB6mgfsTCCaicqGwWg49X/0, createdBy=4a7623908, createdName=sam2000jie, createdTime=Sat Oct 27 06:06:30 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252548, encodeId=8429125254855, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486362, encodeId=71e1148636280, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569026, encodeId=c6be1569026fa, content=<a href='/topic/show?id=5b9ee7968f5' target=_blank style='color:#2F92EE;'>#细胞生长#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77968, encryptionId=5b9ee7968f5, topicName=细胞生长)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75d615484024, createdName=wwzzly, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620241, encodeId=beba16202416a, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Oct 26 17:04:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350536, encodeId=efa235053608, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Oct 26 06:41:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350469, encodeId=17c3350469dd, content=是人们的一种希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69242255430, createdName=121728bam55暂无昵称, createdTime=Thu Oct 25 12:34:15 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350468, encodeId=8224350468ed, content=还没有开始实验还早呢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57b52469453, createdName=12434535m74暂无昵称, createdTime=Thu Oct 25 12:18:49 CST 2018, time=2018-10-25, status=1, ipAttribution=)]
    2018-10-25 12434535m74暂无昵称

    还没有开始实验还早呢!

    0

相关资讯

Cell Res:CD4lowHLA-G+ T细胞的消除能够克服前列腺癌治疗中的雄激素阻断抗性

雄激素阻断治疗(ADT )是前列腺癌(PCa)治疗的一种主要方法,但是在几乎所有的患者中,该疾病都能复发,并且产生雄激素阻断抗性。最近的数据表明了免疫细胞参与了雄激素阻断抗性前列腺癌(CRPC)的发展过程。特别的是,雄激素阻断后,T细胞在PCa患者和小鼠模型中均发生了扩展情况。然而,是否或者哪种T细胞亚型在CRPC的发展过程中具有重要作用仍旧未知。最近,有研究人员鉴定了一个新的CD4lowHLA-

Prostate Cancer P D:经历雄激素阻断治疗前列腺癌男性营养指南研究

最近,有研究人员回顾了有关支持饮食干预能够缓和雄激素阻断治疗(ADT)前列腺癌男性副作用的临床实践证据,并且鉴定了未来研究的重点。研究人员设计了一个分析模型来挑选和说明饮食干预对ADT副作用的影响。研究人员利用关键词鉴定了那些调查饮食干预缓和ADT副作用的前列腺癌男性的相关研究,并涉及了 Medline, Embase, Proquest, CINAHL, Cochrane databases和P

Sci Rep:糖皮质激素能够诱导前列腺癌细胞的治疗抗性相关的应激癌蛋白

糖皮质激素受体(GR)在雄激素受体(AR)信号缺陷时,是前列腺癌(PCa)恶化和治疗抗性产生的重要驱使因子。作为一个旁路机制,GR能够激活AR调控的基因表达,尽管GR靶基因能够导致PCa治疗抗性这一结论还未证明。越来越多的证据表明非裔美国(AA)男性不成比例的发展为恶性PCa,他们对GR信号表现为超敏,并与累积的应激性生活事件有关。最近,有研究人员利用种族多样化的PCa细胞系(MDA-PCa-2b

Prostate Cancer P D:经历前列腺活检男性的直肠穹窿氟喹诺酮抗性细菌预测因子研究

氟喹诺酮(FQ)抗性直肠穹窿菌群与经历经直肠超声引导的前列腺穿刺活检(TRUS-PNB)的男性的感染性并发症相关。最近,有研究人员确定了能够预测FQ抗性直肠培养物的患者因素,这些患者经历了直肠超声引导的前列腺穿刺活检。研究发现,在分析的6179个直肠拭子中,4842(78%)名为FQ敏感性,1337名(22%)为FQ抗性。在单变量分析中,年龄的增加、优先TRUS-PNB、获得的更高的活检核心数目、

Brit J Cancer:准确率达92%!甲基化助力前列腺癌诊断!

前列腺癌(PCa)是老年男性最高发的恶性肿瘤之一,在我国,该病发病率正在快速增长。前列腺癌被称为“沉默的杀手”,不甚明朗的肿瘤分期极易造成“过度治疗”,也可导致疾病进展时的措手不及或无效治疗,因此,找寻可准确分辨前列腺癌真正状态的标志物成为了当务之急。近日,英国和加拿大的科学家们确定了一种可检测的DNA甲基化标记,他们声称该方法可以区分前列腺癌的“侵袭”和“可治”状态,准确率高达92%。换言之,前

Brit J Cancer:前列腺癌中与表型无关的DNA甲基化变化

与人类正常前列腺组织相比,前列腺癌表现出了大量的DNA甲基化变化。然而,在前列腺癌细胞恶性状态相关特征的确定性鉴定中,前列腺癌中具有腔内特征的细胞表现出了明显的优势。最近,有研究人员从前列腺癌和正常组织样本中分离了具有基础和管腔特性的细胞亚群,并对其进行了基因组范围内的DNA甲基化分析。研究人员发现,在正常和癌症样本中,许多之前报道导致前列腺癌的高频DNA甲基化变化在基础细胞和官腔细胞中表现出了差

Baidu
map
Baidu
map
Baidu
map